Actively Recruiting
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil Investigating the Impact of Serum Potassium Levels on Management Strategies for Patients With Hyperkalaemia in Brazilian Clinical Settings
Led by AstraZeneca · Updated on 2026-05-27
6215
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are examining the prevalence and characteristics of hyperkalaemia in adults who have heart failure, diabetes, chronic kidney disease, or high blood pressure. This observational study involves patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in a national campaign for diagnosing hyperkalaemia using point-of-care testing. The study uses anonymized data to explore how common hyperkalaemia is and what demographic and clinical factors are linked to it. The study analyzes anonymized records collected during consultations between April and November 2025. It focuses on adults aged 18 or older of all genders who have the specified health conditions and attended selected clinics. The investigation reviews treatment patterns and risk factors related to blood potassium levels without introducing any new interventions or treatments. Participants' medical histories and potassium test results are reviewed to assess the prevalence and clinical profile of hyperkalaemia over about one year. Researchers will evaluate epidemiological data and the practical and social impact of the condition. The study does not involve active treatment but gathers important health information to better understand hyperkalaemia in clinical settings.
CONDITIONS
Brief Title
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 years or older
- History of heart failure regardless of type
- Diagnosis of chronic kidney disease at any stage
- Diagnosis of diabetes mellitus
- Diagnosis of systemic arterial hypertension
You will not qualify if you...
- Diagnosis of advanced malignant neoplasm undergoing palliative treatment
- Presence of other advanced diseases with life expectancy less than one year
- Lack of information on risk factors for hyperkalaemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 1 year
Participants who attended cardiology, nephrology, or dialysis clinics are observed to describe clinical and demographic profiles, prevalence of hyperkalaemia, and associated risk factors.
Trial Site Locations
Total: 1 location
1
Research Site
Curitiba, Brazil
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here